Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Expects Zeldox Labeling Negotiations To Continue Past September

Executive Summary

Pfizer expects an "approvable" action from FDA in September to set up a final round of negotiations over labeling for the antipsychotic Zeldox, Pfizer Global R&D President John Niblack indicated during a July 27 investor conference call.
Advertisement

Related Content

Organon Antidepressant Ariza Expected In 2002 When Remeron Generics Enter
Organon Antidepressant Ariza Expected In 2002 When Remeron Generics Enter
Pfizer Zeldox Prolongs QT Interval 30 To 60 Msec In 11.6% Of Patients
Pfizer Zeldox Prolongs QT Interval 30 To 60 Msec In 11.6% Of Patients
Zeldox Bold Interaction Warning, Not Black Box, Needed For QTc - Committee
Zeldox Bold Interaction Warning, Not Black Box, Needed For QTc - Committee
Zeldox QTc Prolongation Is Less Severe Than Serlect, Pfizer Tells Committee
Novartis Mellaril Shifted To Second-Line Anti-Psychotic With QTc Black Box
Pfizer Tikosyn Roll-Out Tied To Hospital And Physician Training Program
Advertisement
UsernamePublicRestriction

Register

PS036431

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel